Our goal is to identify small molecule inhibitors against relevant exonucleases to aid existing therapies in oncology. Using a novel, high-throughput activity assays, our aim is to identify small molecule inhibitors for exonucleases that are relevant in the immunotherapy field. Our efforts will aid both radiation and chemotherapeutics treatments to promote IFN-dependent antitumor immunity.